Key Takeaways:
Cardinal Health (NYSE: CAH) reported fiscal third-quarter earnings that beat analyst estimates and raised its full-year profit forecast, signaling sustained momentum in its pharmaceutical and specialty businesses.
"We saw at least double-digit segment profit growth across all five of our operating segments," CEO Jason Hollar said, highlighting broad-based strength that supports the improved outlook for the full year.
The Dublin, Ohio-based company posted a mixed quarter on the top and bottom lines. While revenue missed targets, profitability was a clear bright spot.
The results included an 11% year-over-year revenue increase, though it fell short of the $62.4 billion consensus estimate. GAAP operating earnings decreased 30% to $509 million, reflecting a $184 million goodwill impairment in its Navista & ION unit. However, non-GAAP diluted EPS jumped 35% to $3.17, easily surpassing the $2.81 expected by analysts.
Following the strong profit performance, Cardinal Health raised its fiscal 2026 non-GAAP EPS guidance to a range of $10.70 to $10.80. The company also returned $1.0 billion to shareholders through share repurchases in fiscal 2026.
The Pharmaceutical and Specialty Solutions segment remained the primary growth engine, driven by robust drug demand and expanding specialty services. The performance comes as analysts watch the drug distribution oligopoly, including peers Cencora (NYSE: COR) and McKesson (NYSE: MCK), for their ability to capitalize on demand for high-growth drugs. McKesson recently reported record revenue and raised its own guidance, while William Blair initiated coverage on both McKesson and Cardinal Health with an Outperform rating, citing a "durable competitive moat."
The guidance raise suggests management is confident that momentum from its specialty business and the turnaround in its Global Medical Products and Distribution (GMPD) segment can offset normalizing customer demand and tougher comparisons. Investors will watch for continued margin improvement when the company provides its next update.
This article is for informational purposes only and does not constitute investment advice.
